Table 1. Clinicopathological data of 99 patients with MRCC.
| Characteristics | n | Median | % | Range |
|---|---|---|---|---|
| No. of patients | 99 | |||
| Sex | ||||
| Male | 74 | 74.7 | ||
| Female | 25 | 25.3 | ||
| Age (years) | 65 | 34–83 | ||
| KPS | ||||
| 100% | 69 | 69.7 | ||
| 90% | 18 | 18.2 | ||
| ⩽80% | 12 | 12.1 | ||
| Histology | ||||
| Clear cell | 85 | 85.9 | ||
| Papillary | 12 | 12.1 | ||
| Collecting duct | 2 | 2 | ||
| T stage | ||||
| pT1 | 15 | 15.2 | ||
| pT2 | 12 | 12.1 | ||
| pT3a | 44 | 44.4 | ||
| pT3b | 28 | 28.3 | ||
| Nuclear grade | ||||
| G1 | 3 | 3 | ||
| G2 | 30 | 30.3 | ||
| G3 | 38 | 38.4 | ||
| G4 | 18 | 18.2 | ||
| Not available | 10 | 10.1 | ||
| Nephrectomy | ||||
| Yes | 92 | 92.9 | ||
| No | 7 | 7.1 | ||
| No. of metastatic sites | ||||
| Local recurrence only | 3 | 3 | ||
| 1 site | 33 | 33.3 | ||
| 2 sites | 28 | 28.3 | ||
| 3 sites | 17 | 17.2 | ||
| ⩾4 sites | 18 | 18.2 | ||
| Sites of metastatic disease | ||||
| Lung | 62 | 61.4 | ||
| Mediastinum | 19 | 18.8 | ||
| Bone | 34 | 33.7 | ||
| Liver | 23 | 22.8 | ||
| Abdominal lymph nodes | 14 | 18.9 | ||
| Pancreas | 2 | 2 | ||
| Cerebral | 11 | 10.9 | ||
| Surgery for metastases | ||||
| No metastasectomy | 56 | 56.6 | ||
| Metastasectomy | 43 | 43.4 | ||
| Pulmonary | 11 | 11.1 | ||
| Bone | 27 | 27.3 | ||
| Local recurrence surgery | 5 | 5 | ||
| CNS | 4 | 4 | ||
| Pancreas | 1 | 1 | ||
| Patients receiving metastasectomy twice | 5 | 5 | ||
| Baseline laboratory parameters | ||||
| Haemoglobin normal ⩾11.5 g/dl | 78 | 12.5 | 78.8 | 8.8–16.3 |
| LDH normal <200 U/l | 68 | 176 | 68.7 | 26–2350 |
| CRP normal <0.5 mg/dl | 23 | 2.1 | 23.2 | 0.5–195 |
| aP normal 0–15 U/l | 53 | 111 | 53.5 | 47–819 |
| Best response to outpatient immunotherapy | ||||
| CR | 8 | 8.5 | ||
| PR | 4 | 4.3 | ||
| SD | 33 | 35.2 | ||
| PD | 49 | 49.5 | ||
| Not evaluable | 5 | 5.1 | ||
aP=alkaline phosphatase; CNS=central nervous system; CR=complete response; CRP=C-reactive protein; KPS=Karnofsky performance status; LDH=lactate dehydrogenase; MRCC=metastatic renal cell carcinoma; PD=progressive disease; PR=partial response; SD=stable disease.